Vermox
Efficacy of single doses of mebendazole in the treatment of Trichuris trichiura infection.

Kan SP.

Single doses of 100 mg, 200 mg, 400 mg, and 600 mg of mebendazole in the treatment of very light to heavy Trichuris infections all reduced egg output by over 80%. The egg reduction rates were not affected by increased dosages of mebendazole given in heavier infections. Lower cure rates were obtained in patients with heavier worm burdens despite increased dosages of mebendazole, probably as a result of the diarrhea which is frequently associated with heavy Trichuris infection. A single dose of 600 mg mebendazole in the treatment of very light to very heavy infections gave egg reduction and cure rates similar to those obtained with the recommended multiple-dose regime of 100 mg mebendazole twice a day for 3 consecutive days. The single-dose treatment of Trichuris infections with mebendazole is of considerable public health importance as this single dose regime is easy to administer, well-accepted, well tolerated, less expensive, and has a broad spectrum effect. The risk of erratic migration of Ascaris with single doses of mebendazole does not appear to exceed the risk in a multiple-dose regime.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6824117&dopt=Abstract mebendazole Vermox



Vermox
Mebendazole concentrations in sheep plasma.

Behm CA, Cornish RA, Bryant C.

Formulated mebendazole was administered to sheep by intraruminal injection at dose rates of 12.5, 25, 50 or 100 mg/kg bodyweight. The concentrations of mebendazole and two major metabolites were measured by high-performance liquid chromatography in plasma taken at intervals up to 48 hours after treatment. At 12.5 mg/kg the peak plasma concentration was 0.22 +/- 0.03 microM mebendazole, rising to 0.76 +/- 0.04 microM at 100 mg/kg. Peak plasma concentrations occurred between nine and 24 hours for all dose rates and declined rapidly. Two major metabolites were detected; their concentrations exceeded that of mebendazole at all dose rates.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6836179&dopt=Abstract mebendazole Vermox



Vermox
Evaluation of mebendazole used concurrently with piperazine monohydrochloride in horses.

DiPietro JA, Paul A, Todd KS Jr.

Forty horses from a herd known to have benzimidazole-resistant small strongyles were treated with mebendazole (8.8 mg/kg) or combinations of mebendazole and piperazine monohydrochloride (25, 40, or 55 mg of piperazine base/kg). Pretreatment and 7-day posttreatment fecal examinations were done. Fecal cultures and strongyle egg per gram (epg) counts, and in vitro testing for benzimidazole resistance were performed. Results of fecal examinations prior to treatment were similar in all horses, and results of testing were positive for benzimidazole resistance. Horses treated with mebendazole and piperazine at all dosages had much lower geometric mean strongyle epg counts (2 to 4) and greater percentage reduction in geometric mean strongyle epg counts (99.7 to 99.9) at 7 days after treatment, compared with those measurements for horses treated with mebendazole alone. Adverse reactions to treatment were not observed.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6863123&dopt=Abstract mebendazole Vermox



Vermox
Safety studies evaluating the effect of mebendazole on liver function in dogs.

Van Cauteren H, Marsboom R, Vandenberghe J, Will JA.

The effect of repeated and exaggerated mebendazole administration was evaluated in dogs with and without experimentally induced altered liver function. Irish Setters and Toy Poodles were dosed at 1, 3, and 5 times the therapeutic dose (22 mg/kg) of mebendazole for 17 days, without any effect on the liver. Mixed breed dogs that received increasing doses of mebendazole at 11 to 110 times the therapeutic dose for 2 months did not show adverse effects and remained in good health throughout the experiment. There was not substantial evidence that carbon tetrachloride-induced liver changes were exacerbated by subsequent repeated treatments with mebendazole at 15 times the therapeutic dose. Additionally, in dogs whose liver function was compromised experimentally by glutathione depletion and microsomal enzyme induction, administration of mebendazole at this same dosage for 30 days did not result in any hepatotoxic effect. When mebendazole was given at 15 times the therapeutic dose prior to an hypoxic episode in dogs pretreated with a barbiturate and high protein diet, there was no evidence of any adverse effect on liver function. These metabolic manipulations, in conjunction with mebendazole administration, failed to reveal any mechanism of hepatic dysfunction associated with mebendazole treatment. Unrecognized factors appear to be involved with the rare cases of hepatic dysfunction that have been reported after mebendazole administration. Only careful documentation of field cases and further laboratory research can identify these factors.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6874531&dopt=Abstract mebendazole Vermox



Vermox
Studies on the experimental chemotherapy of Angiostrongylus malaysiensis infection in rats with mebendazole and levamisole.

Ambu S, Kwa BH, Mak JW.

The effect of levamisole hydrochloride and mebendazole on Angiostrongylus malaysiensis infection in albino rats was studied. Animals at different stages of infection were treated with various oral doses of levamisole and mebendazole with the aim of finding an effective treatment regime. Levamisole was most effective for treating rats seven days after infection but its efficacy dropped as infection progressed. Mebendazole given at a dose of 1 mg/kg for five days was more effective against early larval stages (97.39% efficacy). At 5 mg/kg for five days mebendazole was more effective than levamisole against all stages of the infection.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6926760&dopt=Abstract mebendazole Vermox



Vermox
Experience with mebendazole in the treatment of inoperable hydatid disease in England.

Bryceson AD, Cowie AG, Macleod C, White S, Edwards D, Smyth JD, McManus DP.

Eleven heterogeneous patients with inoperable hydatid disease were treated with high doses of oral mebendazole, up to 200 mg/kg/day for 16 to 48 weeks. Toxicity was not encountered. Despite careful assessment it proved difficult critically to evaluate the efficacy of mebendazole. In four patients chemotherapy appeared to have been at least partially successful and success seems to have correlated with serum levels in excess of 100 ng/ml one to three hours after dosage. The problems of assessment are discussed and the need for controlled trials of mebendazole in hydatid disease are stressed.

Online source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6926770&dopt=Abstract mebendazole Vermox